Patients with functional dyspepsia reaped significant benefits from Helicobacter pylori eradication, noted a recent study (Arch Intern Med. 2011;171:1929-1936).
Primary-care patients with functional dyspepsia and H. pylori may have symptoms that are less resistant to treatment than do other patient populations. To examine this, investigators randomized 404 H. pylori-positive adults with functional dyspepsia to treatment with the proton pump inhibitor omeprazole (Prilosec) plus the antibiotics amoxicillin trihydrate and clarithromycin (antibiotics group), or to treatment with omeprazole plus placebo (control group), for 10 days.
Of the 389 participants who completed the study, 49% in the antibiotics group and 36.5% in the control group achieved the primary outcome of at least 50% symptomatic improvement at 12 months. In the patient global assessment of symptoms, 78.1% of the antibiotics users reported that they were better symptomatically, compared with 67.5% of the control group members. The antibiotics users also had a significantly larger increase in their mean Medical Outcomes Study 36-Item Short Form Health Survey physical component summary scores than did the control group.